<DOC>
	<DOCNO>NCT01217476</DOCNO>
	<brief_summary>Trafermin recombinant human basic fibroblast growth factor ( bFGF ; original development code , KCB-1 ) , manufacture genetic engineering use Escherichia coli Kaken Pharmaceutical Co. , Ltd. ( Tokyo , Japan ) . Trafermin 0.01 % cutaneous spray product kit consist glass bottle contain lyophilize trafermin , glass bottle solvent solution spray part fit glass bottle reconstitution final product . We conduct multinational , randomize , double-blind , placebo control , parallel-group , multicentre study consist placebo run-in phase ( 2w ) , treatment phase ( max . 12w ) follow-up phase ( 3mo+6mo ) . The primary objective study demonstrate superior wound closure rate diabetic foot ulcer ( DFUs ) neuropathic origin maximum 12 week topical daily application trafermin 0.01 % spray compare placebo , addition best local care ( off-loading , dressing ) . Approximately 210 patient randomize plan study conduct approximately 40 investigational site Europe .</brief_summary>
	<brief_title>The TRAfermin Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Selection Criteria Patients fulfill follow criterion ( none exclusion criterion describe ) eligible enter placebo runin phase study : 1 . Provide write informed consent participate . 2 . Male female patient age 18 year old . 3 . Type 1 2 diabetes . 4 . A single fullthickness DFU present least 2 week . 5 . DFU wind surface area equal 34 cm2 target foot . 6 . No exposure bone target DFU . 7 . Neuropathy confirm loss protective sensation monofilament test ( SemmesWeinstein 5.07 monofilament ) . 8 . No predominant ischemia require exploration treatment , confirm either : ABPI target leg ( &gt; 0.9 ; equal 1.3 ) ABPI &gt; 1.3 assessable , TBPI target foot Â³above equal 0.7 , OR ABPI target leg ( equal 0.7 equal 0.9 ) ABPI &gt; 1.3 assessable , TBPI target foot &lt; 0.7 , AND toe blood pressure &gt; 40 mmHg Inclusion Criteria Patients fulfill follow criterion eligible randomization : 1 . All selection criterion none exclusion criterion meet . 2 . Completed 2week placebo runin period compliant offload daily application placebo spray , without major protocol violation . Compliance placebo runin treatment regimen must `` excellent '' `` acceptable '' . 3 . Glycosylated hemoglobin ( HbA1c ) equal 10 % ( blood sample take placebo runin period ) . 4 . Noninfected target foot DFU confirm neuropathic origin : ABPI target leg ( &gt; 0.9 ; equal 1.3 ) ABPI &gt; 1.3 assessable , TBPI target foot equal 0.7 , OR ABPI target leg ( equal 0.7 equal 0.9 ) ABPI &gt; 1.3 assessable , TBPI target foot &lt; 0.7 , AND toe blood pressure &gt; 40 mmHg 5 . Target DFU appropriately debrided ( &lt; 10 % black least 50 % red/pink colorimetric scale ) 6 . Target DFU grade A1 A2 University Texas Wound Classification System Grade 1 2 Wagner classification . 7 . DFU surface area equal 0.9 cm2 equal 20 cm2 confirm investigator 's measurement , surface area decrease 40 % compare selection value . Exclusion Criteria Patients fulfill follow criterion eligible enrol study : 1 . Active Charcot foot , inactive Charcot foot , target DFU properly offload . 2 . Ulcers nonneuropathic origin ( e.g. , rheumatoid , radiationrelated , vasculitisrelated ulcer ) . 3 . Presence foot ulcer ( whether target foot ) local systemic antibiotic treatment require . 4 . Evidence skin cancer within adjacent target ulcer . 5 . Any infected ulcer , define problem ( limited ) cellulitis , osteomyelitis , gangrene , deep tissue infection require local systemic antibiotic therapy . 6 . Another wound foot target DFU . ( i.e . Patients another wound limb target DFU eligible study provide concomitant wound infect ankle target foot ) . 7 . Any known active malignancy require general , local , surgical radiation therapy either ongoing within previous 6 month ; patient whose treatment suspend compassionate reason , consider cured malignancy . 8 . Morbid obesity , define body mass index ( BMI ) equal 45 kg/m2 . 9 . Clinically significant medical condition , investigator 's opinion , could impair wound healing ( e.g . hepatic impairment , immunocompromised patient ) . 10 . Severe renal failure , define requirement hemodialysis peritoneal dialysis . 11 . Females pregnant breastfeeding , childbearing potential practicing medically approve method contraception . 12 . Concomitant treatment high dose oral parenteral corticosteroid , define daily dose least 7.5 mg prednisone equivalent . 13 . Participation another clinical study within previous 3 month . 14 . Current participation another clinical study drug device . 15 . History drug alcohol abuse within previous year . 16 . Concurrent severe psychiatric disease ( include severe depressive disorder ) . 17 . Known intolerance IMP excipients . 18 . Known uncooperative noncompliant . 19 . Outpatients unable comply requirement daily spray application home ( either application family member visit nurse ) . 20 . Any condition , opinion investigator , would render patient unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Diabetic foot</keyword>
	<keyword>Neuropathic</keyword>
	<keyword>Wound</keyword>
	<keyword>Growth factor</keyword>
</DOC>